MACROGENICS, INC. Other Noncash Income (Expense)
MACROGENICS, INC. (MGNX) reported Other Noncash Income (Expense) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-03-09
- MACROGENICS, INC. other noncash income (expense) for the quarter ending 2025-12-31 was $0.00.
- MACROGENICS, INC. other noncash income (expense) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- MACROGENICS, INC. other noncash income (expense) for the quarter ending 2024-12-31 was -$57.00K.
- MACROGENICS, INC. other noncash income (expense) for the quarter ending 2024-09-30 was $76.00K.
- MACROGENICS, INC. other noncash income (expense) for fiscal 2025 was $0.00.
- MACROGENICS, INC. other noncash income (expense) for fiscal 2024 was -$2.00K.
- MACROGENICS, INC. other noncash income (expense) for fiscal 2023 was -$423.00K.
- MACROGENICS, INC. other noncash income (expense) for fiscal 2022 was -$2.88M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | |||||
| 2024-12-31 | -$57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $19.00K derived: sum of 2 quarters · filed 2026-03-09 | -$2.00K derived: sum of 3 quarters · filed 2026-03-09 | -$2.00K 10-K · filed 2026-03-09 | ||
| 2024-09-30 | $76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $55.00K derived: sum of 2 quarters · filed 2025-11-12 | $55.00K 10-Q · filed 2025-11-12 | -$2.00K 10-Q · filed 2024-11-05 | $55.00K derived: sum of 4 quarters · filed 2026-03-09 | |
| 2024-06-30 | -$21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$21.00K 10-Q · filed 2025-08-14 | -$21.00K derived: sum of 3 quarters · filed 2026-03-09 | -$105.00K derived: sum of 4 quarters · filed 2026-03-09 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | -$84.00K derived: sum of 3 quarters · filed 2026-03-09 | -$513.00K derived: sum of 4 quarters · filed 2026-03-09 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$84.00K derived: sum of 2 quarters · filed 2026-03-09 | -$513.00K derived: sum of 3 quarters · filed 2026-03-09 | -$423.00K 10-K · filed 2026-03-09 | ||
| 2023-09-30 | -$84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$513.00K derived: sum of 2 quarters · filed 2024-11-05 | -$423.00K 10-Q · filed 2024-11-05 | -$423.00K derived: sum of 4 quarters · filed 2025-03-20 | ||
| 2023-06-30 | -$429.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$339.00K 10-Q · filed 2024-08-06 | -$236.00K 10-Q · filed 2023-08-09 | -$339.00K derived: sum of 3 quarters · filed 2025-03-20 | -$2.14M derived: sum of 4 quarters · filed 2025-03-20 | |
| 2023-03-31 | $90.00K 10-Q · filed 2024-05-09 | $90.00K derived: sum of 2 quarters · filed 2025-03-20 | -$1.72M derived: sum of 3 quarters · filed 2025-03-20 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$1.80M derived: sum of 2 quarters · filed 2025-03-20 | -$2.88M 10-K · filed 2025-03-20 | |||
| 2022-09-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$2.88M 10-Q · filed 2023-11-06 | ||||
| 2022-06-30 | -$1.08M 10-Q · filed 2023-08-09 | |||||
| 2021-12-31 | -$433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$2.04M derived: sum of 2 quarters · filed 2024-03-07 | -$2.04M 10-K · filed 2024-03-07 | |||
| 2021-09-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.60M 10-Q · filed 2022-11-03 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 10-K · filed 2023-03-15 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-02 | |||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |